Informed consent for intravenous contrast-enhanced radiography: a national survey of practice and opinion

A detailed questionnaire regarding the obtaining of patient consent for the administration of intravenous contrast agents was sent to 3845 radiologists in those hospitals across the United States having more than 100 beds. The results represent the current community practice and opinion of the 1547 radiologists (40%) who answered. They showed that 66% of respondents obtained no type of informed consent before injecting intravenous contrast agents. Half of those who did obtain consent did not inform their patients of possible specific major adverse reactions. Half of those who did not obtain consent believed the risk of adverse reaction was remote. Another 40% believed the consent procedure might heighten anxiety and, therefore, increase the risk of reaction. Obtaining informed consent, however, was not significantly associated with an increased incidence of major reactions. Since 8% of the respondents indicated some involvement in malpractice lawsuits regarding the question of informed consent for various procedures, the obtaining of informed consent might lessen the risk of exposure to malpractice litigation. Additional results showed that written consent did not appear to lessen the number of studies performed and that it offered more specific information to the patient regarding complications. Finally, most radiologists (80%) requested a specific policy regarding informed consent from at least one of the following organizations: the American College of Radiology (ACR) (96%), the Radiological Society of North America (RSNA) (26%), state chapters of the ACR (15%).     

浙贝素的结构测定

从浙江产贝母(Fritillaria thunbergii Miq)地上部分分离出一个新的3,7-二氧杂环[3,3,O)辛酮-6类化合物,经光谱(¹HNMR,¹³CNMR,HRMS,EI-MS)及X-单晶衍射数据的分析,确定其结构为2-(3′,5′-dimethoxy-4′-hydroxyphenyl)-3,7-dioxabicyclo[3,3,O]octan-6-one,定名为浙贝素(zhebeiresinol)。